The effect of SOVODAK in the treatment of COVID-19 patients

The effect of adding SOVODAK (sofosbuvir+daclatasvir) to the treatment protocol of COVID-19 outpatients: A Clinical Trial Study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200403046926N1

Enrollment

Registered

2020-04-11

Start date

2020-04-08

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK. Intervention 2: Control group: COVID-19 Patients receiving hydroxychloroquine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis by CT scan with clinical symptoms Consent to attend the study Lymphocyte count less than 1100 Positive CRP test

Exclusion criteria

Exclusion criteria: History of kidney failure Pregnancy Amiodarone consumer

Design outcomes

Primary

Measure	Time frame
Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination.;Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes.;C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test.;Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry.	—

Measure

Time frame

Symptoms ending. Timepoint: During the study. Method of measurement: Clinical examination.;Lymphopenic Status. Timepoint: Before the intervention and the seventh day. Method of measurement: Counting lymphocytes.;C-reactive protein Status. Timepoint: Before the intervention and the seventh day. Method of measurement: C-reactive protein serological test.;Saturation of Peripheral Oxygen. Timepoint: Before the intervention and the seventh day. Method of measurement: Pulseimetry.

—

Secondary

Measure	Time frame
Need hospitalization. Timepoint: Depending on the situation. Method of measurement: Depending on the patient's condition.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Roozbeh

Mazandaran University of Medical Sciences

roozbeh@mazums.ac.ir+98 11 3388 4579

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 17, 2026